BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31597844)

  • 1. New developments in the treatment of follicular lymphoma.
    Leonard JP
    Rinsho Ketsueki; 2019; 60(9):1199-1204. PubMed ID: 31597844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where to start? Upfront therapy for follicular lymphoma in 2018.
    Leonard JP; Nastoupil LJ; Flowers CR
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):185-188. PubMed ID: 30504308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
    Merryman R; Mehtap Ö; LaCasce A
    Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
    Jacobson CA; Freedman AS
    Curr Hematol Malig Rep; 2016 Jun; 11(3):218-23. PubMed ID: 26995595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of obinutuzumab in the management of follicular lymphoma.
    O'Nions J; Townsend W
    Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
    J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating relapsed follicular lymphoma.
    Erblich T; Montoto S
    Expert Rev Hematol; 2018 May; 11(5):403-410. PubMed ID: 29542329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma: 2020 update on diagnosis and management.
    Freedman A; Jacobsen E
    Am J Hematol; 2020 Mar; 95(3):316-327. PubMed ID: 31814159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular lymphoma: 2023 update on diagnosis and management.
    Jacobsen E
    Am J Hematol; 2022 Dec; 97(12):1638-1651. PubMed ID: 36255040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Follicular Lymphoma.
    Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
    Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma.
    Marshall H
    Trends Immunol; 2001 Apr; 22(4):183-4. PubMed ID: 11274916
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel immunotherapy approaches to follicular lymphoma.
    Flowers CR; Leonard JP; Nastoupil LJ
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):194-199. PubMed ID: 30504310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide in follicular lymphoma.
    Flowers CR; Leonard JP; Fowler NH
    Blood; 2020 Jun; 135(24):2133-2136. PubMed ID: 32236519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date.
    Yilmaz U; Salihoglu A; Soysal T
    Drug Des Devel Ther; 2021; 15():3809-3820. PubMed ID: 34522085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of follicular lymphoma: current status.
    Tilly H; Zelenetz A
    Leuk Lymphoma; 2008; 49 Suppl 1():7-17. PubMed ID: 18821428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.